GlobeNewswire Inc | Jan 7, 2021 04:02PM EST

January 07, 2021

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation(Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced thatit will report fourth quarter and full year 2020 financial results on Wednesday, February 10, 2021, after the close of the market.

Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 2:00 p.m. PT, 5:00 p.m. ET, on February 10, 2021, to discuss fourth quarter and full year 2020 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.

Individuals interested in listening to the conference call may do so by dialing:

US domestic callers: (877) 556-5248Outside US callers: (720) 545-0029Please reference Conference ID: 4664638

A live webcast of the conference call will be available online from the Investor Relations page of the Companys website at Events & Presentations. The link will not be active until 1:45 p.m. PT, 4:45 p.m. ET, on February 10, 2021.

After the live webcast, the call will be archived on Fluidigms Investor Relations page at investors.fluidigm.com. In addition, a telephone replay of the teleconference will be available approximately 90 minutes after the end of the call.

The replay dial-in numbers are:

US domestic callers: (855) 859-2056Outside US: (404) 537-3406Please reference Conference ID: 4664638

The telephone replay will be available until February 17.

About FluidigmFluidigm(Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOFand microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visitfluidigm.com.

Fluidigm, theFluidigmlogo, Advanta, and CyTOF are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries. The Advanta Dx SARS-CoV-2 RT-PCR Assay is for In Vitro Diagnostic Use. It is for Use under Emergency Use Authorization Only. Rx Only. Other Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Available InformationWe use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases,SECfilings, public conference calls, and webcasts.

Contact:

Agnes LeeVice President, Investor Relations650 416 7423agnes.lee@fluidigm.com